[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].

Area of Science:

• Oncology
• Immunology
• Medical Research

Background:

• Immunotherapy, specifically immune checkpoint inhibitors, has revolutionized advanced lung cancer care.
• Significant improvements in survival outcomes have been observed in patients with advanced lung cancer.

Purpose of the Study:

• To review the mechanisms of cancer immunotherapy.
• To discuss clinical trials that have altered lung cancer treatment guidelines.
• To explore biomarkers, immune-related adverse events, and future prospects of immunotherapy for advanced non-small cell lung cancer.

Main Methods:

• Literature review of immunotherapy mechanisms.
• Analysis of pivotal clinical trials in advanced lung cancer.
• Compilation of data on biomarkers and adverse events.

Main Results:

• Immune checkpoint inhibitors demonstrate efficacy in advanced lung cancer.
• Key biomarkers are crucial for predicting treatment response.
• Understanding immune-related adverse events is essential for patient management.

Conclusions:

• Immunotherapy represents a paradigm shift in treating advanced non-small cell lung cancer.
• Continued research into biomarkers and management of adverse events will further optimize immunotherapy.